SightLife Surgical acquires Kamra inlay

SightLife Surgical and AcuFocus today announced the companies have agreed to terms for SightLife to acquire the Kamra inlay from AcuFocus.

The Kamra is the first FDA-approved inlay for the surgical correction of presbyopia.

“As we’ve monitored the progress made in the corneal inlay market, we have been impressed with the AcuFocus team and their Kamra inlay technology,” Monty Montoya, CEO of SightLife Surgical, said in a press release on the acquisition. “We look forward to adding this proven technology to SightLife Surgical and carrying forward the development of this segment.”

The terms of the acquisition were not disclosed.

Along with the Kamra acquisition, some members of the AcuFocus team will be joining SightLife Surgical. Patrick Jacques will be vice president of refractive cornea, and Yari L. Mitchell will support the transition as a strategic adviser for SightLife Surgical while maintaining her current role as vice president of medical affairs and business strategy at AcuFocus.   

The press release noted that the companies expect the deal to close at the end of the first quarter of 2018.

SightLife Surgical and AcuFocus today announced the companies have agreed to terms for SightLife to acquire the Kamra inlay from AcuFocus.

The Kamra is the first FDA-approved inlay for the surgical correction of presbyopia.

“As we’ve monitored the progress made in the corneal inlay market, we have been impressed with the AcuFocus team and their Kamra inlay technology,” Monty Montoya, CEO of SightLife Surgical, said in a press release on the acquisition. “We look forward to adding this proven technology to SightLife Surgical and carrying forward the development of this segment.”

The terms of the acquisition were not disclosed.

Along with the Kamra acquisition, some members of the AcuFocus team will be joining SightLife Surgical. Patrick Jacques will be vice president of refractive cornea, and Yari L. Mitchell will support the transition as a strategic adviser for SightLife Surgical while maintaining her current role as vice president of medical affairs and business strategy at AcuFocus.   

The press release noted that the companies expect the deal to close at the end of the first quarter of 2018.